RETRACTED: Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer

Abstract

Objective: This study aims to explore the clinical value of systemic chemotherapy combined with bronchoscopic seed implantation in advanced lung cancer treatment. Methods: The study enrolled 253 patients with advanced lung cancer in Cangzhou People’s Hospital from March 2018 to March 2020, and they were divided into test group and control group. Test group was given systemic chemotherapy combined with bronchoscopic seed implantation, while control group was given systemic chemotherapy. The objective response rate of tumor (ORR), disease control rate (DCR), serum tumor marker level, survival time and adverse reactions of 2 groups were compared. Results: After treatment, the levels of serum tumor markers including carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19 and pro-gastrin-releasing peptide were markedly decreased in test group compared with those in control group ( P < 0.05). Therein, the serum tumor marker level of non-small cell lung cancer (NSCLC) patients was significant decreased compared with that of small cell lung cancer (SCLC) patients in test group. Meanwhile, in test group, the serum tumor marker level of lung adenocarcinoma (LUAD) patients was significant decreased compared with that of lung squamous cell carcinoma (LUSC, P < 0.05). The ORR and DCR in test group were superior to those in control group (63.4%, 92.5% vs 38.7%, 72.3%, P < 0.05), while those were much higher in patients with NSCLC and LUAD relative to those in patients with SCLC and LUSC, respectively ( P < 0.05). Furthermore, the progression-free survival (PFS) and overall survival (OS) in test group were significantly greater than those in control group. In test group, the PFS and OS of patients with NSCLC and LUAD were higher than those of patients with SCLC and LUSC. Conclusion: The efficacy of systemic chemotherapy combined with bronchoscopic seed implantation was superior to that of systemic chemotherapy, which is worthy of promoting in clinical practice.

Based on the Development and Verification of a Risk Stratification Nomogram: Predicting the Risk of Lung Cancer-Specific Mortality in Stage IIIA-N2 Unresectable Large Cell Lung Neuroendocrine Cancer Compared With Lung Squamous Cell Cancer and Lung Adenocarcinoma

“…Of these, about 30% of NSCLC patients with IIIA or IIIB cannot be treated by surgical resection ( 2 ). The majority of patients who lose the chance of surgical treatment reportedly receive platinum-based chemotherapy ( 3 ). Patients with stage III non-surgical lung cancer achieve improved survival by modulating the dose of radiotherapy ( 4 ).…”

Efficacy and safety of Xiao-ai-ping injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: A systematic review and meta-analysis

“…The dose of XAPI was 4~80 mL/day, the course of treatment was 1 to 4 cycles. In these studies, the most common schemes are gemcitabine + cisplatin, [18–22,29,31–37,39] taxol + cisplatin [26–28,30,36,40] and navelbine + cisplatin [23,33–36] schemes. According to the pathological TNM staging of NSCLC, all the patients included in the study were III to IV stage diseases.…”

“…In the included studies, 27 trials [13–28,30–40] reported the ORR of the 2 groups, a total of 1947 patients, including the treatment group (n = 973) and the control group (n = 974). There was no statistical difference between the studies ( P = .97 and I 2 = 0.0%), so the fixed effect model was used.…”

“…A total of 17 trials [13–15,18–21,23–28,31,33,35,38] were included. The results of meta analysis showed that the homogeneity test (χ 2 = 29.30, P = .02, I 2 = 45%), was analyzed by random effect model (RR = 2.12, 95%CI [1.79, 2.50], P < .00001), suggesting that XAPI combined with chemotherapy was significantly better than the control group in improving the quality of life (Fig.…”

“…Included 28 studies published between 2009 and 2020. [13–40] All these studies were carried out in China. Overall, 1947 patients with NSCLC (974 receiving XAPI combined chemotherapy and 973 receiving chemotherapy alone) were identified and included in this meta-analysis.…”